Summary by Futu AI
Alterity Therapeutics has released its Corporate Governance Statement for the fiscal year ended June 30, 2024, outlining its commitment to maintaining high ethical standards and statutory compliance. The statement details the company's governance framework aligned with ASX Corporate Governance Council's Principles and Recommendations.The Board structure comprises 4 directors, all male, with extensive industry experience and professional qualifications. The company maintains two key committees: Audit and Remuneration, both chaired by independent directors. The workforce demonstrates gender diversity with 47% female representation, though all board positions are currently held by men.The statement highlights robust risk management processes, remuneration policies, and disclosure practices. Key features include regular board performance reviews, a comprehensive code of conduct, and policies on anti-bribery, whistleblowing, and continuous disclosure. The company emphasizes shareholder engagement through various communication channels and maintains transparency in financial reporting.
